---
schema_version: "secwatch.filing_event.v1"
accession: "0001159036-24-000049"
form_type: "8-K"
ticker: "HALO"
cik: "0001159036"
company_name: "HALOZYME THERAPEUTICS, INC."
filed_at: "2024-10-31T23:59:59+00:00"
generated_at: "2026-05-30T07:17:30.214276+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Halozyme Q3 revenue up 34% to $290M; raises full-year guidance on strong royalty growth

## Summary
- Total revenue $290.1M (+34% YoY); royalty revenue $155.1M (+36% YoY).
- GAAP diluted EPS $1.05 (+72% YoY); Non-GAAP diluted EPS $1.27 (+69% YoY).
- 2024 guidance raised: revenue $970M-$1.02B, Adj. EBITDA $595M-$625M, Non-GAAP EPS $4.00-$4.20.
- argenx expanded ENHANZE deal (4 new targets) for $30M upfront; ViiV added another target.
- Cash and securities $666.3M, up from $336M at Dec 2023, driven by operations.

## SEC filing metadata
- accession: 0001159036-24-000049
- form_type: 8-K
- ticker: HALO
- cik: 0001159036
- company_name: HALOZYME THERAPEUTICS, INC.
- filed_at: 2024-10-31T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1159036/000115903624000049/0001159036-24-000049-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1159036/000115903624000049/halo-20241031.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001159036-24-000049
- JSON: https://secwatch.observer/filing/0001159036-24-000049.json
- Plain text: https://secwatch.observer/filing/0001159036-24-000049.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.